Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic and pharmacokinetic predictors of response to induction TPF chemotherapy in advanced head and neck squamous cell carcinoma
2008-006874-14Phase 4Completed
- Sponsor
- CHU Nîmes
- Start
- Apr 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of docetaxel, cisplatin and fluorouracil in head and neck squamous cell carcinoma (HNSCC), sponsored by CHU Nîmes. Primary endpoints: Predictive criteria for response to chemotherapy and Correlations between molecular, pharmacogenetic, and pharmacokinetic parameters and treatment efficacy/toxicity. Started Apr 2009; status: completed.
02
Drugs
docetaxelcisplatinfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2008-006874-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-006874-14.